References

Releasing the brakes on cancer immunotherapy

10.1016/j.cell.2015.08.038 · 2015 · External reference

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

10.1038/s41571-021-00552-7 · 2022 · External reference

Therapeutic cancer vaccines revamping: Technology advancements and pitfalls

10.1016/j.annonc.2021.08.2153 · 2021 · External reference

Cell-based drug delivery systems participate in the cancer immunity cycle for improved cancer immunotherapy

10.1002/smll.202205166 · 2023 · External reference

Therapeutic cancer vaccines

10.1038/s41568-021-00346-0 · 2021 · External reference

In situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases

10.1016/j.apsb.2024.06.003 · 2024 · External reference

Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation

10.1038/s41467-023-40207-y · 2023 · External reference

A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice

10.1038/s41467-024-54650-y · 2024 · External reference

Advances in nanotechnology-augmented T cell-based novel cancer immunotherapies

10.26599/nr.2025.94908299 · 2026 · External reference

Dendritic cells as orchestrators of anticancer immunity and immunotherapy

10.1038/s41571-024-00859-1 · 2024 · External reference

Decisions about dendritic cells: Past, present, and future

10.1146/annurev-immunol-100311-102839 · 2012 · External reference

Click-chemistry-mediated cell membrane glycopolymer engineering to potentiate dendritic cell vaccines

10.1002/anie.202315782 · 2024 · External reference

Taking dendritic cells into medicine

10.1038/nature06175 · 2007 · External reference

Cancer immunotherapy via dendritic cells

10.1038/nrc3258 · 2012 · External reference

Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer

10.1126/science.adh4567 · 2024 · External reference

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy

10.1038/s41375-023-01980-3 · 2023 · External reference

Dendritic cell-based immunotherapy

10.1038/cr.2016.157 · 2017 · External reference

Melanoma-secreted lysosomes trigger monocyte-derived dendritic cell apoptosis and limit cancer immunotherapy

10.1158/0008-5472.can-19-2944 · 2020 · External reference

A therapeutic DC vaccine with maintained immunological activity exhibits robust anti-tumor efficacy

10.1016/j.jconrel.2022.06.059 · 2022 · External reference

An essential role for Akt1 in dendritic cell function and tumor immunotherapy

10.1016/j.annemergmed.2006.07.468 · 2006 · External reference

Cross-presentation by dendritic cells

10.1038/nri3254 · 2012 · External reference

DNA engineered lymphocyte-based homologous targeting artificial antigen-presenting cells for personalized cancer immunotherapy

10.1021/jacs.1c09316 · 2022 · External reference

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

10.1038/s43018-020-0075-x · 2020 · External reference

3D-printed dendritic cell vaccines for post-surgery cancer immunotherapy

10.1002/adfm.202400507 · 2024 · External reference

A dendritic cell-nanogel conjugate for tumor-draining lymph node-specific PD-L1 blockade

10.1002/adma.202504733 · 2025 · External reference

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

10.1126/scitranslmed.aav7431 · 2020 · External reference

Immune checkpoint therapy-current perspectives and future directions

10.1016/j.cell.2023.03.006 · 2023 · External reference

Cancer immune evasion, immunoediting and intratumour heterogeneity

10.1038/s41577-024-01111-8 · 2025 · External reference

A universal therapeutic vaccine leveraging autologous pre-existing immunity to eliminate in situ uniformly engineered heterogeneous tumor cells

10.1002/adma.202412430 · 2025 · External reference

Cancer vaccines as enablers of immunotherapy

10.1038/s41590-025-02308-2 · 2025 · External reference

Designing nanotheranostics with machine learning

10.1038/s41565-024-01753-8 · 2024 · External reference

Metal-phenolic outer membrane vesicles for cancer radioimmunotherapy

10.1021/jacs.5c02774 · 2025 · External reference

A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy

10.1038/s41565-025-01952-x · 2025 · External reference

Engineering cellular vesicles for immunotherapy

10.1021/accountsmr.4c00362 · 2025 · External reference

Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment

10.1038/s41467-025-60448-3 · 2025 · External reference

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

10.1038/s41565-022-01098-0 · 2022 · External reference

Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence

10.1126/sciadv.ade0625 · 2023 · External reference

Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy

10.1038/s41467-023-42155-z · 2023 · External reference

Leveraging senescent cancer cell membrane to potentiate cancer immunotherapy through biomimetic nanovaccine

10.1002/advs.202400630 · 2024 · External reference

STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy

10.1016/j.bioactmat.2024.09.002 · 2024 · External reference

Direct presentation of tumor-associated antigens to induce adaptive immunity by personalized dendritic cell-mimicking nanovaccines

10.1002/adma.202205950 · 2022 · External reference

Biomimetic nanovesicle vaccines derived from dendritic cells sensitized with whole tumor antigens for melanoma immunotherapy

10.1016/j.mtbio.2025.102409 · 2025 · External reference

Cellular senescence is immunogenic and promotes antitumor immunity

10.1158/2159-8290.cd-22-0523 · 2023 · External reference

Senescent cancer cell-derived nanovesicle as a personalized therapeutic cancer vaccine

10.1038/s12276-023-00951-z · 2023 · External reference

Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine

10.1038/s41467-023-40886-7 · 2023 · External reference

CCR7 and its ligands: Balancing immunity and tolerance

10.1038/nri2297 · 2008 · External reference

Application of nano-delivery systems in lymph nodes for tumor immunotherapy

10.1007/s40820-023-01125-2 · 2023 · External reference

A minimalist pathogen-like sugar nanovaccine for enhanced cancer immunotherapy

10.1002/adma.202410715 · 2024 · External reference

Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells

10.1038/s41551-024-01309-0 · 2025 · External reference

Nanoinducer-mediated mitochondria-selective degradation enhances T cell immunotherapy against multiple cancers

10.1038/s41565-025-01909-0 · 2025 · External reference

Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity

10.1126/sciimmunol.adp7302 · 2024 · External reference